BioMark's Liquid Biopsy Platform Takes A Major Step Forward in Breast Cancer Diagnosis with AI-powered ER Status Prediction
BioMark Diagnostics (CSE: BUX, OTC: BMKDF) announced a breakthrough in breast cancer diagnostics with a blood-based assay that can predict estrogen receptor (ER) status with 93% accuracy. The study, published in the International Journal of Molecular Sciences, demonstrates how the company's liquid biopsy platform combines metabolomics and machine learning to identify unique metabolic signatures for ER-positive and ER-negative tumors.
The company will present additional findings about plasma metabolomics in lobular breast cancer biomarker discovery at the 47th San Antonio Breast Cancer Symposium on December 11th, 2024. This research showcases the platform's ability to differentiate between breast cancer subtypes, specifically lobular breast cancer and ductal carcinoma.
BioMark Diagnostics (CSE: BUX, OTC: BMKDF) ha annunciato una svolta nella diagnosi del cancro al seno con un saggio basato su sangue in grado di prevedere lo stato del recettore degli estrogeni (ER) con un 93% di accuratezza. Lo studio, pubblicato nell'International Journal of Molecular Sciences, dimostra come la piattaforma di biopsia liquida dell'azienda combini metabolomica e apprendimento automatico per identificare firme metaboliche uniche per i tumori ER-positivi e ER-negativi.
L'azienda presenterà ulteriori risultati sulla metabolomica plasmatica nella scoperta di biomarcatori per il cancro mammario lobulare al 47° Simposio Internazionale sul Cancro al Seno di San Antonio, che si terrà l'11 dicembre 2024. Questa ricerca mette in luce la capacità della piattaforma di differenziare tra i sottotipi di cancro al seno, in particolare il cancro mammario lobulare e il carcinoma duttale.
BioMark Diagnostics (CSE: BUX, OTC: BMKDF) anunció un avance en el diagnóstico del cáncer de mama con un ensayo basado en sangre que puede predecir el estado del receptor de estrógeno (ER) con una precisión del 93%. El estudio, publicado en el International Journal of Molecular Sciences, demuestra cómo la plataforma de biopsia líquida de la compañía combina metabolómica y aprendizaje automático para identificar firmas metabólicas únicas para tumores ER-positivos y ER-negativos.
La empresa presentará hallazgos adicionales sobre metabolómica plasmática en el descubrimiento de biomarcadores del cáncer de mama lobulillar en el 47º Simposio del Cáncer de Mama de San Antonio, que se llevará a cabo el 11 de diciembre de 2024. Esta investigación muestra la capacidad de la plataforma para diferenciar entre subtipos de cáncer de mama, específicamente el cáncer lobulillar y el carcinoma ductal.
BioMark Diagnostics (CSE: BUX, OTC: BMKDF)는 93% 정확도로 에스트로겐 수용체 (ER) 상태를 예측할 수 있는 혈액 기반 검사로 유방암 진단의 혁신을 발표했습니다. 국제 분자 과학 저널에 발표된 이 연구는 회사의 액체 생검 플랫폼이 대사체학 및 기계 학습을 결합하여 ER-양성 및 ER-음성 종양의 독특한 대사 서명을 식별하는 방법을 보여줍니다.
회사는 2024년 12월 11일 47회 샌안토니오 유방암 심포지엄에서 로불라 유방암 바이오표지자 발견을 위한 혈장 대사체학에 대한 추가 결과를 발표할 예정입니다. 이 연구는 유방암의 아형을 구분하는 플랫폼의 능력을 특히 로불라 유방암과 관암종 간에 드러냅니다.
BioMark Diagnostics (CSE: BUX, OTC: BMKDF) a annoncé une avancée dans le diagnostic du cancer du sein avec un test sanguin capable de prédire l'état des récepteurs aux œstrogènes (ER) avec une précision de 93%. L'étude, publiée dans l'International Journal of Molecular Sciences, démontre comment la plateforme de biopsie liquide de l'entreprise combine métabolomique et apprentissage automatique pour identifier des signatures métaboliques uniques pour les tumeurs ER-positives et ER-négatives.
L'entreprise présentera des résultats supplémentaires sur la métabolomique plasmatique dans la découverte de biomarqueurs pour le cancer du sein lobulaire lors du 47ème Symposium sur le Cancer du Sein de San Antonio, qui se tiendra le 11 décembre 2024. Cette recherche met en lumière la capacité de la plateforme à différencier les sous-types de cancer du sein, en particulier le cancer lobulaire et le carcinome canalaire.
BioMark Diagnostics (CSE: BUX, OTC: BMKDF) hat einen Durchbruch in der Diagnostik von Brustkrebs mit einem blutbasierten Test angekündigt, der den Status des Östrogenrezeptors (ER) mit 93% Genauigkeit vorhersagen kann. Die Studie, veröffentlicht im International Journal of Molecular Sciences, zeigt, wie die flüssige Biopsie-Plattform des Unternehmens Metabolomik und maschinelles Lernen kombiniert, um einzigartige metabolische Signaturen für ER-positive und ER-negative Tumoren zu identifizieren.
Das Unternehmen wird am 11. Dezember 2024 beim 47. San Antonio Breast Cancer Symposium zusätzliche Erkenntnisse zur Plasma-Metabolomik in der Entdeckung von Biomarkern für lobulären Brustkrebs präsentieren. Diese Forschung unterstreicht die Fähigkeit der Plattform, zwischen Brustkrebs-Subtypen, insbesondere lobulärem Brustkrebs und duktalem Karzinom, zu unterscheiden.
- Achieved 93% accuracy in predicting ER status using blood-based assay
- Successfully developed non-invasive breast cancer diagnostic test
- Platform demonstrates capability to detect cancer stages, subtypes, and receptor status
- None.
BioMark Expands Its Liquid Biopsy Platform Receptor Status for Breast Cancer
Vancouver, British Columbia--(Newsfile Corp. - December 10, 2024) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark"), a leader in liquid biopsy tests for early cancer detection, announced a significant advancement in its breast cancer diagnostic capabilities. A groundbreaking study published in the International Journal of Molecular Sciences (IJMS) Special Edition demonstrates the potential of BioMark's blood-based assay to accurately predict estrogen receptor (ER) status in breast cancer patients. This non-invasive test, leveraging metabolomics and machine learning, holds promise to revolutionize breast cancer diagnosis and treatment.
Researchers analyzed blood samples from breast cancer patients and healthy controls, identifying unique metabolic signatures associated with ER-positive and ER-negative tumors. Utilizing advanced machine learning, researchers achieved an impressive
Building upon this progress in breast cancer diagnosis, BioMark continues its commitment to innovation by presenting new findings at the upcoming 47th San Antonio Breast Cancer Symposium (SABCS). On December 11th, 2024, during a poster session, Dr. Jean-François Haince, General Manager and CSO, will share data highlighting how plasma metabolomics can be applied to lobular breast cancer biomarker discovery. These insights emphasize the power of machine learning techniques in analyzing complex metabolomic data and identifying significant biomarkers that can differentiate between different subtypes of breast cancer, specifically lobular breast cancer and ductal carcinoma.
Mr. Bux further adds, "The company remains dedicated to developing accurate and accessible tools for early cancer diagnosis, extending beyond lung and breast cancer to explore its platform's potential for other cancer types and improved overall patient outcomes."
About BioMark Diagnostics Inc.
BioMark Diagnostics Inc. is a leading developer of liquid biopsy tests for the early detection of cancer that leverages the power of metabolomics and machine learning algorithms. The company's proprietary technology utilizes a simple blood draw to detect the presence of cancer-associated biomarkers, enabling earlier diagnosis and improved patient outcomes. The technology can also be used for measuring response to treatment and potentially for serial monitoring of cancer survivors. BioMark is committed to developing innovative and accessible diagnostic solutions to address unmet medical needs in oncology.
Further information about BioMark is available under its profile on the SEDAR+ website www.sedarplus.ca and the CSE website https://thecse.com/.
For further information on BioMark, please Contact:
Rashid Ahmed Bux
President & CEO
BioMark Diagnostics Inc.
Tel. 604-370-0779
Email: info@biomarkdiagnostics.com
Forward-Looking Information:
This press release may include forward-looking information within the meaning of Canadian securities legislation, concerning the business of BioMark. Forward-looking information is based on certain key expectations and assumptions made by the management of BioMark. Although BioMark believes that the expectations and assumptions on which such forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because BioMark can give no assurance that they will prove to be correct. Forward-looking statements contained in this press release are made as of the date of this press release. BioMark disclaims any intent or obligation to update publicly any forward-looking information, whether as a result of new information, future events, or results or otherwise, other than as required by applicable securities laws.
The CSE has not reviewed, approved, or disapproved the content of this press release.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/233122
FAQ
What accuracy rate did BioMark's (BMKDF) breast cancer diagnostic test achieve?
What technology does BioMark (BMKDF) use in its breast cancer diagnostic platform?
When will BioMark (BMKDF) present its findings at the San Antonio Breast Cancer Symposium?
